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ABSTRACT
Treatment of advanced cutaneous T-cell lymphomas (CTCL) is challenging 
because they are resistant to conventional chemotherapy. USP2 has been shown to 
promote resistance to chemotherapeutic agents in several cancer models.
We show here USP2 is expressed in quiescent and activated T-cells and its 
expression is 50% lower in CTCL cell lines (MyLa2000, SeAx and Hut-78) than in 
normal T-cells. USP2 is expressed in neoplastic cells in early, plaque-stage mycosis 
fungoides (MF) and is downregulated in advanced tumor stages. Upon treatment with 
psoralen with UVA (PUVA) or a p53 activator, nutlin3a, USP2 expression is significantly 
increased in MyLa2000 (p53wt/wt), but not in SeAx (p53mut) or Hut-78 (p53-/-). USP2 
knockdown decreases MyLa2000 cell viability after PUVA by 50% but not Hut-78, 
suggesting that the function of USP2 in CTCL cells is p53-dependent. Furthermore, 
USP2 knockdown results in a decreased Mdm2 expression and upregulation of p53. 
Taken together, our findings suggest that USP2 stabilizes Mdm2 which antagonizes 
pro-apoptotic activity of p53 and possibly contributes to therapeutic resistance in 
CTCL.
INTRODUCTION
Cutaneous T-cell lymphomas (CTCL) are 
extra-nodal lymphomas arising from skin-homing 
T-lymphocytes. Mycosis fungoides (MF) and Sézary 
syndrome (SS) are the most common entities. MF typically 
presents as skin patches and/or plaques, which can 
progress to skin tumours, with subsequent involvement 
of lymph nodes, peripheral blood, and visceral organs 
[1, 2]. In early stages, the disease can be controlled by 
skin-directed therapies such as psoralen with UVA 
photochemotherapy (PUVA), ionizing radiation, topical 
chemotherapy or topical corticosteroids. In the advanced, 
aggressive stages, CTCL is an incurable disease in which 
the 5-year mortality exceeds 50% [3, 4].
Deubiquitinating enzymes (DUBs) are known as one 
of the largest protein family which regulates the ubiquitin–
proteasome system [5]. Ubiquitin-specific proteases (USP) 
comprise the largest subfamily in DUBs with more than 
60 members. USPs counteracts proteasome degradation of 
proteins by deconjugating ubiquitin from substrates and 
from ubiquitin chains [6].
Alterations in ubiquitin-proteasome system are 
observed in the pathogenesis of many human diseases, 
including cancer [7], inflammatory and autoimmune 
diseases [8] and viral diseases [9]. The proteasome 
inhibitor bortezomib is approved for the treatment 
of multiple myeloma and mantle cell lymphoma, 
underscoring the hypothesis that the ubiquitin–
proteasome system can be therapeutically targeted in 
cancer. Although bortezomib showed effect in CTCL, 
the dose-limiting toxicities and drug-resistance restrict 
the use of this drug [10, 11]. A promising alternative to 
targeting the proteasome itself would be to interact with 
the USPs to generate more specific, less toxic anticancer 
agents [12].
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It has been previously shown that USP2 has 
oncogenic properties. USP2a is overexpressed in human 
prostate adenocarcinomas, and upregulation of USP2 
prevents cancer cells from apoptosis upon treatment 
with chemotherapeutic agents [13–15]. Moreover, USP2 
has been shown to restrain proteasomal degradation of 
specific proteins involved in different cellular pathways, 
such as Mouse double minute 2 homolog (Mdm2), 
MdmX, fatty acid synthase (FASN), apoptosis inducing 
factor (AIF), cyclin D, Aurora-A kinase and epidermal 
growth factor receptor (EGFR) [16–22]. The function 
of USP2 in CTCL has not been studied. Here, we found 
that USP2 showed decreased expression in advanced 
CTCL compared with the early stage disease and blocked 
apoptosis in malignant p53wt T-lymphocytes. We propose 
that a negative regulatory loop in which USP2 is induced 
by PUVA via p53 increases cell resistance to apoptosis via 
deubiquitination of Mdm2.
RESULTS
USP2 is expressed in CTCL
Using qPCR, the expression of the three known 
USP2 isoforms was determined in the material from 
paraffin-embedded biopsies from plaque/patch and 
tumor MF [23]. The expression of USP2b and UBP41 
was not detected (data not shown). USP2a was 
expressed in both patch/plaque MF and tumor MF with 
2.3 fold lower expression in the tumors (Figure 1a). In 
addition, we confirmed the presence of the protein by 
immunohistochemistry in the corresponding paraffin-
embedded samples (Figure 1b). USP2 was detectable in 
keratinocytes, fibroblasts, and dermal T-cells. There were 
no obvious differences in USP2 immunoreactivitivity in 
keratinocytes and fibroblasts between the plaques and the 
tumors of MF (data not shown). However stronger USP2 
Figure 1: USP2 is expressed in CTCL with a stage-dependant manner. Analysis of USP2 mRNA expression in paraffin-
embedded biopsies from MF-plaque (n=5) and MF-tumor (n=13) a. and in quiescent lymphocytes and a panel of cell lines, Psor-2, 
MyLa2000, Hut-78 and SeAx c. by qPCR. Data was normalized to GAPDH and expressed as relative units (RU). Unpaired T-test was 
used to calculate P-value. Columns, mean (n = 3); error-bars, SD. b. USP2 protein expression in 5 MF-plaque and MF-tumor was detected 
by immunohistochemistry. Red color indicates USP2 expression. Bar=50μm. Arrows highlight lymphoma cells. d. Analysis of USP2 
knockdown in MyLa2000 cell viability. Columns, mean (n = 8); paired T-test was used to calculate P-value, error-bars, SEM. PI-negative 
cells represent viable cells.
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staining was observed in lymphoma cells in the plaques 
than in the tumors (Figure 1b). Moreover, we determined 
the expression of USP2 in quiescent lymphocytes from 
healthy individuals (n=3), a T-cell cell line from a psoriasis 
patient (Psor-2), representing activated T-lymphocytes 
[24] and a panel of CTCL cell lines, MyLa2000 cells, 
SeAx and Hut-78 cells. The highest USP2 expression 
was detected in quiescent T-cells and Psor-2 and 50% 
lower USP2 expression was seen in MyLa2000 cells. The 
downregulation was even more pronounced in Hut-78 
and SeAx cells (Figure 1c). The finding that USP2 was 
decreased in CTCL comparing to normal T-cells suggested 
that USP2 had a pro-apoptotic property. Therefore we 
investigated proliferation and viability in MyLa2000 
cells after silencing of USP2 with siRNA. The efficiency 
of the transfection was confirmed by qPCR (Figure S1). 
MyLa2000 cells proliferation was not changed (Figure 
S2) Surprisingly, USP2 knockdown reduced viability of 
MyLa2000 cells (Figure 1d).
USP2 is upregulated by PUVA and a p53 
activator, nutlin3a
Since PUVA is a first-line therapy for MF [25], we 
aimed to determine whether USP2 reduced cell sensitivity 
to this treatment. The kinetics of USP2 expression was 
examined in MyLa2000 cells for 4 to 72 hours after 
PUVA treatment. PUVA caused a significant (P<0.01) 
upregulation of USP2 mRNA expression already after 8 
hours with an even stronger increase after 24 and 48 hours 
post-treatment (Figure 2a). USP2 protein expression was 
increased 2.2 fold and 2.5 fold 48h and 72h after PUVA, 
respectively. Mdm2 and p53 were also induced by PUVA 
(Figure 2b).
P53 is a major pro-apoptotic protein and unlike in 
many cancers it is rarely mutated in early MF [26–29]. 
Nutlin-3a is a known activator of p53 acting via disruption 
of p53-Mdm2 interaction and causes apoptosis in 
MyLa2000 which has intact p53, but not in SeAx and Hut-
Figure 2: USP2 is induced by PUVA and a p53 activator, nutlin3a. p53wt CTCL cell line, MyLa2000, was subjected to PUVA 
a, b. or 5μM nutlin3a c-d. as shown in Methods. USP2 expression was measured by qPCR (a, c) and western blot (WB) (b, d) 2h-72h 
after the treatments. For qPCR, data was normalized to GAPDH and expressed as relative units (RU). The experiments were repeated 3 
times, unpaired T-test was used to calculate P-value, error-bars, SD, *, P<0.05; **, P<0.01. For WB, Mdm2 and p53 protein level was also 
measured. β-actin was used as internal control, and relative protein expression levels are reported below the corresponding western blot 
bands. Representative data was shown.
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78 which have mutated p53 [29, 30]. Nutlin3a treatment 
caused a significant upregulation of p53 and Mdm2 protein 
expression in MyLa2000 cells (Figure 2d) accompanied by 
the upregulation of p53 target, p21 and Mdm2 (Figure S3). 
Nutlin 3a also caused an increase in USP2a mRNA and a 
2.7-fold and 1.9-fold increase in USP2 protein expression 
24h and 48h after treatment, respectively (Figure 2c, 2d).
Knockdown of USP2 sensitizes MyLa2000 cells 
to PUVA and nutlin3a treatment
USP2 was downregulated in advanced stage 
CTCL and induced by PUVA and p53 activator, nutlin3a, 
suggesting that USP2 acted as a survival stress response 
to prevent lymphoma cells from apoptosis. Therefore 
we investigated whether apoptosis caused by PUVA 
or nutlin3a in MyLa2000 cells can be aggravated by 
knockdown of USP2. The efficiency of transfection was 
confirmed by qPCR (Figure S1). Silencing of USP2 
sensitized MyLa2000 cells to apoptosis after treatment 
with PUVA or nutlin3a (Figure 3a, 3b).
USP2 reduces cell apoptosis via p53 signaling
To further confirm that p53 signaling was involved 
in the regulation of USP2, we investigated whether USP2 
was inducedby nutlin3a or PUVA in the other CTCL 
cell lines with functional p53 signaling (Mac2a) and 
impaired p53 signaling, SeAx (p53mut) and Hut-78 (p53-
/-) [29]. USP2 mRNA expression was increased in Mac2a 
upon both treatments, indicating that the upregulation of 
USP2 was not MyLa2000 cells-specific (Figure 4a). As 
expected, USP2 mRNA expression was not increased 
by 5uM nutlin3a in SeAx or Hut-78 (Figure 4a). More 
importantly, PUVA did not upregulate USP2 mRNA 
expression in Hut-78 cells and only slightly in SeAx cells 
(Figure 4a). Moreover, the effect of nutlin3a in USP2 
mRNA expression was examined in MyLa2000 cells with 
knockdown of p53. USP2 was induced in MyLa2000 cells. 
However, the induction of USP2 was significantly lower 
in MyLa2000 with silenced p53 (Figure 4b). Knockdown 
of USP2 did not increase cell apoptosis in Hut-78 cells 
compared to cells with control siRNA, further suggesting 
the pivotal role of p53 in USP2 function (Figure 4c).
Knockdown of USP2 decreases Mdm2 protein 
level and increases p53 transcriptional activity
It was previously shown that USP2 stabilized Mdm2 
in NTERA-2 testicular embryonal carcinoma cells, which 
express wild-type p53 and Mdm [17]. To test whether 
USP2 could block p53 via Mdm2, we silenced USP2 
and measured Mdm2 level by western blot in MyLa2000 
cells after nutlin3a treatment. USP2 knockdown resulted 
in 30% and 40% lower Mdm2 protein expression in 
nutlin3a-nontreated and treated cells, respectively. The 
expression of p53, was increased by nutlin3a in cells with 
USP2 knockdown to a higher extent than in the control 
MyLa2000 cells treated by scrambled oligonucleotide 
(Figure 5a). In addition, we also investigated whether 
the knockdown of USP2 and nutlin3a in combination 
increased p53 transcriptional activity. The upregulation of 
p21 was used to indicate the increased p53 transcriptional 
activity. As shown in Figure 5b, USP2 knockdown 
significantly increased p21 mRNA expression compared 
with MyLa2000 cells with control siRNA (p<0.05) 
(Figure 5b). These results suggested that activated p53 
increased USP2, which in turn counteracted the pro-
apoptotic activity of p53, forming a negative feedback 
loop (Figure 5c).
DISCUSSION
Modification of the ubiquitin-proteasome system 
has emerged as a strategy for cancer treatment [6, 31]. 
In this study, we show for the first time the function of 
USP2a in CTCL. USP2a has been investigated in many 
types of cancers, including prostate cancer [15], gliomas 
[32], ovarian serous cystadenocarcinoma [33] and 
bladder cancer [14] where its expression correlated with 
cancer grade with higher expression in advance stages. 
Surprisingly, expression of USP2a was highest in normal 
T-lymphocytes and further decreased in advanced CTCL. 
These results implicated that unlike the situation seen in 
solid tumors, USP2a may be a tumor suppressor in CTCL. 
However, we refuted this hypothesis by showing that a 
knockdown of USP2a promoted apoptosis of MyLa2000 
cells. Moreover, USP2 silencing enhanced apoptosis after 
PUVA treatment in MyLa2000 suggesting that USP2 
enhanced therapeutic resistance. It would be interesting 
to investigate whether USP2 aggravates the resistance to 
other therapeutic modalities, such as ionizing radiation or 
ultraviolet B.
Mechanistically we were able to demonstrate that 
the activation of p53 upregulated USP2. First, a selective 
p53 activator nutlin3a increased USP2a in p53wt CTCL 
cell lines, MyLa2000 and Mac2a, but not in p53 impaired 
CTCL cell lines. Second, the increase of USP2a after 
PUVA was absent or largely diminished in the cell lines 
with mutated p53 (Hut-78 and SeAx). A slight increase of 
USP2 expression in SeAx cells after PUVA is compatible 
with the residual activity of mutated p53 in this cell line. 
Third, the induction of USP2 in MyLa2000 cells was 
significantly lower upon knockdown of p53 after treatment 
of nutlin3a. Finally, the knockdown of USP2 in Hut-78 
cells did not increase apoptosis after PUVA, in contrast to 
what was observed in MyLa2000 with intact p53.
Although we were able to demonstrate that USP2 
stabilized Mdm2, we do not have direct evidence to 
postulate that this is due to the changes in deubiquitination 
of the protein. A direct measurement of the levels of 
ubiquitinated Mdm2 should be performed to unequivocally 
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Figure 3: USP2 silencing promotes apoptosis in MyLa2000 cells upon PUVA or nutlin3a treatment. USP2 knockdown 
enhances MyLa2000 apoptosis upon PUVA a. and nutlin3a b. treatment. MyLa2000 cells were transfected with USP2 siRNA or siRNA 
control. After 24h the cells were treated with the indicated dosage of PUVA and nutlin3a. 24h post nutlin3a and 48h post PUVA stimulation, 
cells were staining with annexin V and PI for flow cytometry, as described in Methods. Left: comparison of cell viability between cells with 
USP2 siRNA and siRNA control after treatment. Values are means of three independent experiments, paired T-test was used to calculate 
P-value, Error-bars, SEM. *, P<0.05; **, P<0.01. Right: The dot-plot graphs are representative of three independent experiments.
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Figure 4: The upregulation of USP2 is p53-dependent. a. USP2 expression is induced by nutlin3a and PUVA in Mac2a with 
functional p53, but not in Hut-78 and SeAx cells with impaired p53. USP2 expression was examined in Hut-78, SeAx and Mac2a cells 
treated with nutlin3a and PUVA as shown in figure 2. The experiment was repeated 3 times. Unpaired T-test was used to calculate P-value, 
error-bars, SD. b. Knockdown of p53 reduces induction of USP2 expression upon nutlin3a treatment. USP2 expression was checked in 
MyLa2000 cells with silenced p53 24h after nutlin3a treatment. Values are means of three independent experiments, paired T-test was used 
to calculate P-value, Error-bars, SEM. c. Hut-78 apoptosis is not increased upon USP2 knockdown after PUVA treatment. The experiment 
was performed and presented as described in figure 3. Paired T-test was used to calculate P-value, Error-bars, SEM.
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link USP2 deubiquitinase activity with the Mdm2-p53 
signaling.
Taken together, we show for the first time that 
USP2 may be anti-apoptotic in CTCL and antagonize the 
effect of PUVA. We postulate that upregulation of USP2 
antagonizes p53 effect via deubiquitination of Mdm2. In 
the future, targeting USP2 may be utilized in the therapy 
of CTCL.
MATERIALS AND METHODS
Clinical samples, cell culture and reagents
Formalin-fixed, paraffin-embedded biopsies taken 
from 5 patients with the MF plaques (Stage IA-IB) (3 
males and 2 females; mean age 68 years; range 49 to 
87 years) and 13 MF tumors (Stage IIB) (7 males and 
6 females; mean age 65 years; range 47 to 91 years) 
were obtained from the Department of pathology, 
Rigshospitalet. Four CTCL cell lines were used: 
MyLa2000, derived from a plaque biopsy of a patient 
with MF [34], SeAx [35] and Hut-78 [36], derived from 
peripheral blood of patients with SS, Mac2a (Davis et 
al., 1992), derived from different clinical specimens of a 
patient showing progression from lymphomatoid papulosis 
to anaplastic large-cell lymphoma. Cells were maintained 
as described [37, 38]. Briefly, MyLa2000 and SeAx cells 
were cultured in Gibco GlutaMAX (Invitrogen, Carlsbad, 
CA) supplemented with 10% fetal bovine serum at 37°C 
under 5% CO2. Hut-78 and Mac2a cells were cultured in 
RPMI-1640 containing 2 mm l-glutamine and 10% fetal 
bovine serum. Psor-2 was isolated from involved skin of 
a psoriatic donor [24] and were maintained in RPMI-1640 
containing 2 mm l-glutamine and 10% human serum. 
Nutlin-3a was obtained from Cayman Chemical (Ann 
Arbor, MI), and methoxsalen, also known as 8-MOP, was 
purchased from Sigma-Aldrich (St. Louis, MO).
For PUVA, cells were incubated with 1μM 
methoxsalen (8-MOP) for 2h prior to 0.4, 0.8 or 1.6 J/cm2 
UVA exposure. Control was cells treated with 8-MOP, but 
no UVA irradiation.
Figure 5: USP2 inhibits the cellular actions of p53 through Mdm2. a. USP2 knockdown decreased Mdm2 expression. MyLa2000 
cells were transfected with either siRNA control or USP2 siRNA for 24h, followed by treatment with 5μM nutlin3a for 24h. Western blot 
was used for detecting USP2, Mdm2 and p53 protein level. β-actin was used as internal control, and relative protein expression levels are 
reported below the corresponding western blot bands. The experiment was repeated 3 times. Representative data was shown. b. USP2 
knockdown increase p53 transcription activity. The expression of p21 was used to indicate p53 transcription activity. qPCR was applied 
to examine p21 expression in MyLa2000 cells transfected with siUSP2/siRNA with or without nutlin3a treatment. Paired T-test was used 
to calculate P-value. c. A proposed model for the regulation of USP2. PUVA and nutlin3a activate p53 and promote cell apoptosis. USP2 
is induced by PUVA and nutlin3a and increases cell resistance to apoptosis via modulation of Mdm2/p53 interaction, constituting an anti-
apoptosis protective loop.
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siRNA transfections
For both MyLa2000 and Hut-78 cells, transfection 
was carried out using Amaxa machine (Lonza, Basel, 
Switzerland) and Nucleofector Kit-T (Cat VCA-
1002) according to manufacturer’s instruction. Briefly, 
10x106 cells were centrifuged at 90g for 6 minutes and 
resuspended in 100 μl Nucleofector® Solution combined 
with siNRAs at room temperature. 50 nM small interfering 
RNA was used for the specific knockdown of USP2 (Santa 
Cruz Biotechnology, Texas, USA) and p53 (Thermo 
Scientific, Chicago, USA). Silencer select negative 
control #1 (Ambion Inc., Austin, TX, USA) was used as 
negative control. Cell/siRNA suspension was transferred 
into certified cuvette, and Nucleofector® Program T-016 
was chose for MyLa2000 cells and V-001 was used for 
Hut-78 cells. Efficiency of transfection was evaluated at 
mRNA level by RT-PCR (Figure S1) and at protein level 
by western blot analysis.
RNA extraction
Total RNA from paraffin-embedded blocks was 
extracted by applying RNeasy FFPE Kit (Qiagen, Venlo, 
Limburg, Netherlands) according to manufacturer’s 
instruction. Briefly, 10μm thick sections were cut from 
FFFE blocks and 6 sections from each block were placed 
into a microcentrifuge tube for RNA extraction. The 
sections were treated with 320μl deparaffinization buffer 
(Qiagen) and 240μl buffer PKD. The customized protocol, 
RNeasy FFPE - 3-8 FFPE tissue sections – Standard, was 
selected to perform RNA extraction in QIAcube (Qiagen).
Total RNA from cells was prepared using QIAcube. 
The protocol, RNeasy Mini - Animal tissues and cells 
– Standard, was applied to extract RNA. The RNA 
concentration was determined by spectrophotometry. 
Total RNA (0.5μg) was reversed transcribed into cDNA 
in a 20μl reaction by RevertAid™ First Strand cDNA 
Synthesis Kit (Thermo Scientific). The resulting cDNA 
was diluted with 80μl dH2O to obtain a concentration of 
5 ng/μl cDNA.
Quantitative real-time PCR
For the quantification of Mdm2, USP2 and p21, 20 
ng of cDNA per reaction were amplified in the presence 
of TaqManR universal master mix (Applied Biosystems, 
Foster City, CA) and TaqMan® Gene Expression Assay: 
Mdm2 (Hs01066930-m1), USP2 (Hs00899199-g1), p21 
(Hs00355782-m1), GAPDH (Hs02758991_g1)(Applied 
Biosystems) (stage 1, 50°C for 2 min, stage 2, 95°C for 10 
min and stage 3, 95°C for 15 s, 60°C for 1 min, repeated 
45 times) in Stratagene Mx3005p (Aglicent Technologies, 
Santa Clara, CA). Target gene expression was normalized 
based on the values of the expression of GAPDH (Applied 
Biosystems).
Apoptosis assessment
In order to assess the apoptotic rate, MyLa2000 
cells and Hut-78 were transfected with USP2 siRNA and 
control siRNA, followed by treatment with PUVA or 
nutlin3a. 24h or 48h after treatment, cells were double-
stained with annexin V-FITC and PI according to the 
manufacturer’s protocol (Beckman-Coulter, Fullerton, 
CA) and analyzed by flow cytometry (Beckman-Coulter, 
Fullerton, CA) as described previously [39, 40].
Western blotting and immunohistochemistry
MyLa2000 cell were lysed for protein expression 
by western blotting. The protein concentration was 
determined by Pierce™ BCA Protein Assay Kit (Thermo 
Scientific) according to manufacturer’s instruction. The 
primary antibodies used were USP2 (8036s diluted 1:500) 
from Cell Signaling (Danvers, Massachusetts, USA), anti-
Mdm2 (33-7100 diluted 1:500) from Invitrogen (Carlsbad, 
CA) and anti-p53 (M3629 diluted 1:500) from DAKO 
(Glostrup, Denmark). Equal amounts of protein were 
loaded in a 4-12% Bis-Tris gel (Bio-Rad Laboratories, 
Hercules, CA) and separated by electrophoresis at 200 
V followed by electrophoretic transfer to a nitrocellulose 
membrane (Bio-Rad Laboratories). Membranes were then 
blocked with Odyssey® blocking agent (Li-Cor, Lincoln, 
NE) for 1 hour at 4°C. Primary mouse or rabbit antibodies 
were applied overnight at 4°C followed by incubation 
with the appropriate secondary antibodies DyLight 800 
conjugate (anti-rabbit) (Thermo Scientific) or Alexa Fluor 
680 (anti-mouse) (Invitrogen Cooperation, Carlsbad, CA) 
for 2h at room temperature. Expression was detected and 
quantified with the infrared Odyssey imaging System (Li-
Cor). USP2 protein expression was analysed in formalin-
fixed paraffin-embedded skin sections using rabbit anti-
human USP2 antibody (ab101609 diluted 1:100) from 
Abcam (Cambridge, UK) and anti-rabbit conjugated with 
HRP (P 0448) (DAKO) at 1: 200 dilution. Sections were 
mounted using Glycergel® Mounting Medium, Aqueous 
(DAKO). The omission of the primary antibody in the 
staining procedure was used as a negative control.
Statistics
Two-sided heteroscedastic Student’s t-test was used 
for two-group comparisons of continuous data, Paired 
or unpaired as indicated in the figure caption. A p-value 
less than 0.05 was considered statistically significant. 
Continuous data are reported as means with standard 
deviation (SD) or standard error of the mean (SEM) 
as noted in figure caption. Real Time-PCR data were 
analyzed using the ΔΔCT method. Statistical analysis was 
performed by R (version 3.1.0, Vienna, Austria) or Excel 
(Microsoft Corp., Redmond, WA).
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